Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Shares Outstanding (Diluted Average) (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Shares Outstanding (Diluted Average) for 14 consecutive years, with $85.4 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 9.36% to $85.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $85.4 million through Dec 2025, up 9.36% year-over-year, with the annual reading at $85.4 million for FY2025, 9.36% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $85.4 million at Niagen Bioscience, down from $86.6 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $86.6 million in Q3 2025, with the low at $64.2 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $74.4 million, with a median of $75.0 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) grew 12.66% in 2021, then rose 0.5% in 2022.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $67.2 million in 2021, then rose by 3.79% to $69.7 million in 2022, then grew by 7.54% to $75.0 million in 2023, then rose by 4.19% to $78.1 million in 2024, then rose by 9.36% to $85.4 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $85.4 million, $86.6 million, and $84.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.